OpiCalc Logo

OpiCalc

--- Clinical Tools

Logo
OpiCalc
7-Point Dermoscopy ChecklistAJCC Melanoma Staging (8th Ed)ALDEN Algorithm (Drug Causality for SJS/TEN)BWH High-Risk SCC StagingBody Surface Area (BSA)Breslow Thickness and Clark LevelDLQIEASI ScoreMSK Melanoma NomogramMelanoma RiskPASI ScorePOEM (Patient-Oriented Eczema Measure)RegiSCAR Criteria for DRESSSCORADSCORTENmPASI (Modified PASI)

Clinical Evidence and Methodology

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

When to Use

  • To predict the mortality risk in patients with Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
  • To guide triage decisions (e.g., admitting to an ICU or specialized Burn Unit).
CLINICAL INSIGHT

How it Works

Risk Factors (1 point each)

  • Age > 40 years
  • Heart rate > 120 beats/minute
  • Presence of malignancy (cancer)
  • Body surface area (BSA) detached or compromised > 10% on Day 1
  • Blood Urea Nitrogen (BUN) > 28 mg/dL (>10 mmol/L)
  • Serum Glucose > 252 mg/dL (>14 mmol/L)
  • Serum Bicarbonate < 20 mEq/L

Interpretation (Mortality Rate)

  • Score 0-1: ~3.2%
  • Score 2: ~12.1%
  • Score 3: ~35.3%
  • Score 4: ~58.3%
  • Score ≥ 5: >90%
CLINICAL INSIGHT

Practical Pearls

Clinical Pearls

  • Must be calculated within the first 24 hours of admission, and ideally repeated on Day 3 for the most accurate prognostic trajectory.
  • Heavily weights end-organ stress (tachycardia, uremia, acidosis, hyperglycemia) rather than purely dermatologic signs.
CLINICAL INSIGHT

Next Steps

Critical Actions

Scores ≥ 2 warrant immediate transfer to a specialized Burn Center or Medical ICU, early ophthalmologic consultation, and cessation of all suspected offending drugs.

CLINICAL INSIGHT

Evidence Base

Primary Reference

SCORAD

SCORAD Index: Unified assessment of Atopic Dermatitis severity (Area, Intensity, Symptoms).
0%0%100%

erythema

edema

crusting

excoriation

lichenification

dryness

0010
0010
EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

When to Use

  • Evaluating the severity of atopic dermatitis (eczema) objectively.
  • Monitoring disease progression and treatment response over time.
  • Standardized reporting in clinical trials for atopic dermatitis therapies.
CLINICAL INSIGHT

How it Works

Formula

Variables

  • A: Extent of disease as percentage of Body Surface Area (BSA) affected (0-100).
  • B: Intensity of 6 specific morphologic lesions (erythema, edema/papulation, oozing/crusts, excoriations, lichenification, and dryness/xerosis) graded 0-3. Max 18.
  • C: Subjective symptoms (pruritus and sleep loss) over the last 3 days, graded 0-10 on VAS. Max 20.
CLINICAL INSIGHT

Practical Pearls

Clinical Pearls

  • Dryness (xerosis) is evaluated ONLY on uninvolved skin areas.
  • It combines both objective physician assessment and subjective patient-reported outcomes, making it very comprehensive.
  • A score > 50 indicates severe atopic dermatitis.
CLINICAL INSIGHT

Next Steps

Interpretation

  • < 25: Mild disease.
  • 25 - 50: Moderate disease.
  • > 50: Severe disease. Consider escalation to systemic immunosuppression or biologics.